Company record
BioSpectra, Inc.
0 FDA warning letters since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about BioSpectra, Inc..
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Oct 14 | Class II | BioSpectra, Inc. Drug |
Biospectra Tris/Tromethamine, USP, GMP, API Grade, Manufactured at 100 Majestic Way, Bangor, PA 18013, NDC 64173-101-25 Failed stability specifications |